Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (135)

« Back to Publications

Guideline for the management of hepatitis B and C infection and subsequent liver disease surveillance (where indicated) in people with congenital bleeding disorders: A joint guideline from the British Society of Haematology and the British Viral Hepatitis Group.

Brown A. et al, (2025), Br J Haematol

Frailty and frailty syndromes in persons with hemophilia: a review.

McKeown W. et al, (2025), J Thromb Haemost, 23, 3409 - 3423

Temporal trends in hospital-recorded pulmonary embolism in England before, during and after the COVID-19 pandemic (2008-2024): a population-based observational study.

Zhong X. et al, (2025), Lancet Reg Health Eur, 58

Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' Organisation.

Wall C. et al, (2025), Res Pract Thromb Haemost, 9

Same-day emergency care: a retrospective observational study of the incidence and predictors of venous thromboembolism following hospital-based acute ambulatory medical care.

Shapiro S. et al, (2025), J Thromb Haemost, 23, 97 - 107

UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults.

Chowdary P. et al, (2025), Haemophilia, 31, 26 - 38

Prevention and management of venous thromboembolism

Curry N. and Shapiro S., (2025), 921 - 931

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.

Madan B. et al, (2024), J Thromb Haemost, 22, 1880 - 1893

Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).

Fischer K. et al, (2024), Res Pract Thromb Haemost, 8

Multiple myeloma and its treatment contribute to increased platelet reactivity.

Mitchell JL. et al, (2023), Platelets, 34

Frailty and haemophilia; speaking the language of geriatricians.

Sangha G. et al, (2023), Haemophilia, 29, 1371 - 1375

Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.

Funding E. et al, (2023), Adv Ther, 40, 3770 - 3783

Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability.

Mitchell JL. et al, (2023), Res Pract Thromb Haemost, 7

Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).

Wall C. et al, (2023), Haemophilia, 29, 743 - 752

Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.

Zwagemaker A-F. et al, (2023), J Thromb Haemost, 21, 850 - 861

Load More

1
2
3
4
5
6
7
...
»